HUMACYTE INC
NASDAQ: HUMA (Humacyte, Inc.)
Last update: 1 hour ago0.597
0.03 (4.59%)
| Previous Close | 0.570 |
| Volume | 5,172,296 |
| Price / Earnings (Forward) | 35.84 |
| Price / Sales | 52.31 |
| Price / Book | 5.07 |
| 52 Weeks Range |
| Operating Margin (TTM) | -4,484.33% |
| Diluted EPS (TTM) | -0.690 |
| Total Debt/Equity (MRQ) | 228.93% |
| Current Ratio (MRQ) | 3.68 |
| Operating Cash Flow (TTM) | -99.38 M |
| Levered Free Cash Flow (TTM) | -67.40 M |
| Return on Assets (TTM) | -42.82% |
| Return on Equity (TTM) | -249.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Humacyte, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 20.16% |
| % Held by Institutions | 40.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Antipodes Partners Ltd | 30 Jun 2026 | 10,103,647 |
| Great Point Partners I Lp | 30 Jun 2026 | 3,750,000 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JONES KEITH ANTHONY | 0.681 | - | 10,000 | 6,810 |
| Aggregate Net Quantity | 10,000 | |||
| Aggregate Net Value ($) | 6,810 | |||
| Aggregate Avg. Buy ($) | 0.681 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JONES KEITH ANTHONY | Director | 20 Aug 2026 | Buy (+) | 10,000 | 0.681 | 6,810 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |